Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Jan 4;145(1):61-78.
doi: 10.1161/CIRCULATIONAHA.121.056171. Epub 2021 Dec 29.

Colchicine in Cardiovascular Disease: In-Depth Review

Spyridon G Deftereos  1 , Frans J Beerkens  2 , Binita Shah  3 , George Giannopoulos  4 , Dimitrios A Vrachatis  1 , Sotiria G Giotaki  1 , Gerasimos Siasos  1 , Johny Nicolas  2 , Clare Arnott  5   6 , Sanjay Patel  6 , Mark Parsons  7 , Jean-Claude Tardif  8 , Jason C Kovacic  2   9   10 , George D Dangas  1   2
Affiliations
Review

Colchicine in Cardiovascular Disease: In-Depth Review

Spyridon G Deftereos et al. Circulation. .

Abstract

Inflammation plays a prominent role in the development of atherosclerosis and other cardiovascular diseases, and anti-inflammatory agents may improve cardiovascular outcomes. For years, colchicine has been used as a safe and well-tolerated agent in diseases such as gout and familial Mediterranean fever. The widely available therapeutic has several anti-inflammatory effects, however, that have proven effective in a broad spectrum of cardiovascular diseases as well. It is considered standard-of-care therapy for pericarditis, and several clinical trials have evaluated its role in postoperative and postablation atrial fibrillation, postpericardiotomy syndrome, coronary artery disease, percutaneous coronary interventions, and cerebrovascular disease. We aim to summarize colchicine's pharmacodynamics and the mechanism behind its anti-inflammatory effect, outline thus far accumulated evidence on treatment with colchicine in cardiovascular disease, and present ongoing randomized clinical trials. We also emphasize real-world clinical implications that should be considered on the basis of the merits and limitations of completed trials. Altogether, colchicine's simplicity, low cost, and effectiveness may provide an important addition to other standard cardiovascular therapies. Ongoing studies will address complementary questions pertaining to the use of low-dose colchicine for the treatment of cardiovascular disease.

Keywords: atrial fibrillation; cerebrovascular; colchicine; coronary artery disease; disorders; inflammation; percutaneous coronary intervention; pericarditis; postpericardiotomy syndrome.

PubMed Disclaimer

Figures

Figure 1.
Figure 1.. Inflammation in cardiovascular disease and anti-inflammatory targets of colchicine and canakinumab.
Colchicine has broad anti-inflammatory effects, here illustrated here in atherosclerosis. Colchicine inhibits (1) neutrophil migration, adhesion, activation, (2), neutrophil release of defensins, MMP, and elastin, (3) NLRP3 activation of the inflammatory pathway with release of IL-1β, in turn activating IL-6, and eventually stimulation CRP, and (4) smooth muscle proliferation and vascular stenosis. (5) Canakinumab is a monoclonal antibody that specifically targets the upstream inflammatory mediator IL-1β. CRP = C-reactive protein; IL = Interleukin; MMP = Matrix Metalloproteinases, NLRP3 = NLR Family Pyrin Domain Containing 3, TGF = transforming growth factor
Figure 2.
Figure 2.. Various CYP-3A4- and P-glycoprotein inhibitors that effect colchicine metabolism.
CYP-3A4- and P-glycoprotein inhibitors may alter the liver and kidney’s ability to clear colchicine. Concomitant administration of strong inhibitors with colchicine should generally be avoided, while moderate/mild inhibitors may cautiously be used with colchicine through dose reductions and shared decision making. P-gp = P-glycoprotein. Figure designed with BioRender.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Nerlekar N, Beale A and Harper RW. Colchicine — a short history of an ancient drug. Medical Journal of Australia 2014;201:687–688. - PubMed
    1. Imazio M and Nidorf M. Colchicine and the heart. European Heart Journal 2021. - PMC - PubMed
    1. Beck C, Morbach H, Richl P, Stenzel M and Girschick HJ. How can calcium pyrophosphate crystals induce inflammation in hypophosphatasia or chronic inflammatory joint diseases? Rheumatol Int 2009;29:229–238. - PubMed
    1. Esatoglu SN and Hatemi G. Update on the treatment of Behçet’s syndrome. Intern Emerg Med 2019;14:661–675. - PubMed
    1. O’Gara PT, Kushner FG, Ascheim DD, Casey DE Jr., Chung MK, de Lemos JA, Ettinger SM, Fang JC, Fesmire FM, Franklin BA, et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2013;127:e362–425. - PubMed

Publication types

MeSH terms